Eflimrufusp alfa

伊立芙普α

Report date: 2025/09/30 09:59:30

Base Information

Drug NameEflimrufusp alfa
Drug Alias NameRC28-ERC28-E注射液伊立芙普α眼内注射液RC28-ERC-28-E +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionFibroblast growth factors antagonistsVascular endothelial growth factor inhibitors
TargetsFibroblast growth factorsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesRemeGen Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSanten Pharmaceutical China Co LtdRemeGen Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degenerationDiabetic Retinopathy
Inactive IndicationsMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A